ClinicalTrials.gg
CompletedNCT04409262REMDACTAUpdated Feb 14, 2022Results posted

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

A Phase 3 interventional study of Remdesivir and Tocilizumab in COVID-19 Pneumonia, sponsored by Hoffmann-La Roche. Completed at 54 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-02-14.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
649
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing tocilizumab in COVID-19 — 3 open to participants now, 4 under way, 2 of them phase 3. tocilizumab · COVID-19.

Enrollment
5th of 38
649 · median 150
Started
2020
with 33 others
Phase 3
13 of 38
2 open now
Registered
22nd of 38
by date
Lead sponsor
4 of 38
Hoffmann-La Roche

Among the 38 studies testing tocilizumab in COVID-19, this one is the 5th largest by enrollment, is one of 34 that started in 2020, is one of 13 in phase 3, and was the 22nd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 38 studies testing tocilizumab in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing tocilizumab in COVID-19, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.

03

Conditions studied

  • COVID-19 Pneumonia
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized with COVID-19 pneumonia confirmed per a positive polymerase chain reaction (PCR) of any specimen (e.g., respiratory, blood, urine, stool, other bodily fluid) and evidenced by chest X-ray or CT scan
  • Requiring more than 6 L/min supplemental oxygen to maintain SpO2 > 93%
  • Agrees to not participate in another clinical trial for the treatment of COVID-19 while participating in this study

Exclusion criteria

Exclusion Criteria

  • Known severe allergic reactions to tocilizumab or other monoclonal antibodies
  • Known to remdesivir, the metabolites, or formulation
  • Active tuberculosis (TB) infection
  • Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)
  • In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments
  • Treatment with or immunomodulatory therapy (including tocilizumab) within the past 3 months
  • Concurrent treatment with other agents with actual or possible direct-acting antiviral activity against SARS-CoV-2 within 24 hours prior to study drug dosing. In addition, participants with prior or current treatment with > 2 doses of remdesivir for COVID-19 are excluded
  • Participating in other drug clinical trials
  • Estimated (eGFR) \< 30 mL/min (including patients receiving hemodialysis or hemofiltration)
  • (ALT) or aspartate aminotransferase (AST) > 5 x (ULN) detected within 24 hours of screening (according to local laboratory reference ranges)
  • (ANC) \< 1000/uL at screening
  • count \< 50,000/uL at screening
  • Body weight \< 40 kg
  • Treatment with an drug within 5 half-lives or 30 days (whichever is longer) of randomization
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
649 participants (actual)

Study arms

  • Experimental
    Remdesivir + Tocilizumab (RDV+TCZ)

    Participants assigned to the RDV+TCZ arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ on Day 1.

    Drug: Remdesivir · Drug: Tocilizumab

  • Active comparator
    Remdesivir + Placebo (RDV+Placebo)

    Participants assigned to the RDV+ placebo arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ-placebo on Day 1.

    Drug: Remdesivir · Drug: Placebo

Interventions

  • Participants will receive intravenous (IV) RDV

  • Participants will receive IV TCZ

  • DrugPlacebo

    Participants will receive IV placebo matched to TCZ

06

What researchers measure

Primary outcomes

  1. Time to Hospital Discharge or "Ready for Discharge" up to Day 28

    Defined as days from randomization to hospital discharge or "Ready for Discharge" not followed by ordinal scale category \>1, hospital readmission or death. Hospital discharge or "Ready for Discharge" is defined as an ordinal score of 1 on the 7-point ordinal scale. Participants who die are censored at Day 28. 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

    Time frame: Up to Day 28

Secondary outcomes

  1. Time to Mechanical Ventilation or Death up to Day 28

    Time to Mechanical Ventilation or Death defined as the time from randomization to the first occurrence of death or mechanical ventilation. For participants already on mechanical ventilation at baseline, only death is counted as an event.

    Time frame: Up to Day 28

  2. Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 14

    Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

    Time frame: Day 14

  3. Time to Death up to Day 28

    Time to death is defined as the time from randomization to death.

    Time frame: Up to Day 28

  4. Time to Death up to Day 60

    Time to death is defined as the time from randomization to death.

    Time frame: Up to Day 60

  5. Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-category Ordinal Scale of Clinical Status up to Day 28

    Defined as time from randomization to the time when at least a 2-category improvement in the 7-category ordinal scale is observed. Patients who die are censored at day 28. Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

    Time frame: Up to Day 28

  6. Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 7

    Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

    Time frame: Day 7

  7. Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 21

    Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

    Time frame: Day 21

  8. Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 28

    Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

    Time frame: Day 28

  9. Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 60

    Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

    Time frame: Day 60

  10. Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline (Participants Who Did Not Require Mechanical Ventilation at Baseline)

    Day 28: Participants who withdraw or die prior to Day 28 are assumed to have required mechanical ventilation. Participants without mechanical ventilation prior to discharge are assumed not to have required mechanical ventilation unless they die by Day 28, which are counted as an event. Day 60: Participants who withdraw or die prior to Day 60 are assumed to have required mechanical ventilation. Participants without mechanical ventilation prior to discharge are assumed not to have required mechanical ventilation unless they die by Day 60, which are counted as an event.

    Time frame: Day 28 and Day 60

  11. Proportion of Participants Who Are Alive and Free of Respiratory Failure at Day 28 and Day 60 (Participants Requiring Mechanical Ventilation at Baseline)

    Time frame: Day 28 and Day 60

  12. Duration of Mechanical Ventilation (Participants Requiring Mechanical Ventilation at Baseline) up to Day 28

    Participants who die by Day 28 are assigned a duration of 28 days.

    Time frame: Up to Day 28

  13. Difference in Mortality at Days 14, 28, and 60

    Time frame: Days 14, 28, and 60

  14. Time to Recovery up to Day 28

    Defined as the time from randomization to the time when an ordinal scale category of 2 (non-ICU hospital ward or "ready for hospital ward" not requiring supplemental oxygen) or better is observed, not followed by ordinal scale category \>2 or death. Participants who die are censored at day 28. 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

    Time frame: Up to Day 28

  15. Proportion of Participants Who Are Discharged or "Ready for Discharge" up to Day 28

    Defined as hospital discharge or "Ready for Discharge" not followed by ordinal scale category \>1, hospital readmission or death. 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

    Time frame: Up to Day 28

  16. Proportion of Participants Who Require Initiation of Mechanical Ventilation Post-baseline or Die up to Day 28

    Participants already on mechanical ventilation at baseline are only counted as an event if death occurs.

    Time frame: Up to Day 28

Other outcomes

  1. Percentage of Participants With Adverse Events (AEs) Tabulated by Severity

    AEs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4: Life-threatening consequences; urgent intervention indicated Grade 5: Death related to AE Participants are counted at the highest AE grade experienced.

    Time frame: Up to Day 60

  2. Proportion of Participants With Any Post-Treatment Infection

    Time frame: Up to Day 60

07

Results

Posted Feb 14, 2022

Participant flow

Participants with severe COVID-19 pneumonia

Participant flow — Overall Study
MilestoneRemdesivir + Placebo (RDV+PBO)Remdesivir + Tocilizumab (RDV+TCZ)
Started215434
Completed140300
Not completed75134
Withdrew: Adverse event02
Withdrew: Death5597
Withdrew: Lost to follow-up1223
Withdrew: Lack of staff01
Withdrew: Protocol violation31
Withdrew: Withdrawal by subject510

Outcome measures

PrimaryTime to Hospital Discharge or "Ready for Discharge" up to Day 28

Defined as days from randomization to hospital discharge or "Ready for Discharge" not followed by ordinal scale category \>1, hospital readmission or death. Hospital discharge or "Ready for Discharge" is defined as an ordinal score of 1 on the 7-point ordinal scale. Participants who die are censored at Day 28. 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

Time frame:
Up to Day 28
Reported as:
Median · days
Time to Hospital Discharge or "Ready for Discharge" up to Day 28
daysRemdesivir + Placebo (RDV+Placebo) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Time to Hospital Discharge or "Ready for Discharge" up to Day 2814.0 (11.0 to 16.0)14.0 (12.0 to 15.0)
Statistical analysis
  • Remdesivir + Placebo (RDV+Placebo) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Log Rank · p = 0.7414 · Hazard ratio (hr): 0.965 · 95% CI 0.78 to 1.19
SecondaryTime to Mechanical Ventilation or Death up to Day 28

Time to Mechanical Ventilation or Death defined as the time from randomization to the first occurrence of death or mechanical ventilation. For participants already on mechanical ventilation at baseline, only death is counted as an event.

Time frame:
Up to Day 28
Reported as:
Median · Days
Time to Mechanical Ventilation or Death up to Day 28
DaysRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Time to Mechanical Ventilation or Death up to Day 28NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Log Rank · p = 0.8993 · Hazard ratio (hr): 0.980 · 95% CI 0.72 to 1.34
SecondaryClinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 14

Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

Time frame:
Day 14
Reported as:
Number · Percentage of Participants
Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 14
Percentage of ParticipantsRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Category 152.454.0
Category 21.92.6
Category 311.48.9
Category 46.79.6
Category 56.74.9
Category 611.410.0
Category 79.510.0
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Regression, Logistic · p = 0.7648 · Odds ratio (or): 1.05 · 95% CI 0.77 to 1.44
SecondaryTime to Death up to Day 28

Time to death is defined as the time from randomization to death.

Time frame:
Up to Day 28
Reported as:
Median · Days
Time to Death up to Day 28
DaysRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Time to Death up to Day 28NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Log Rank · p = 0.7867 · Hazard ratio (hr): 0.948 · 95% CI 0.65 to 1.39
SecondaryTime to Death up to Day 60

Time to death is defined as the time from randomization to death.

Time frame:
Up to Day 60
Reported as:
Median · Days
Time to Death up to Day 60
DaysRemdesivir + Placebo (RDV+Placebo) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Time to Death up to Day 60NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Remdesivir + Placebo (RDV+Placebo) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Log Rank · p = 0.4602 · Hazard ratio (hr): 0.882 · 95% CI 0.63 to 1.23
SecondaryTime to Improvement of at Least 2 Categories Relative to Baseline on a 7-category Ordinal Scale of Clinical Status up to Day 28

Defined as time from randomization to the time when at least a 2-category improvement in the 7-category ordinal scale is observed. Patients who die are censored at day 28. Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

Time frame:
Up to Day 28
Reported as:
Median · Days
Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-category Ordinal Scale of Clinical Status up to Day 28
DaysRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-category Ordinal Scale of Clinical Status up to Day 2811.0 (10.0 to 13.0)12.0 (11.0 to 13.0)
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Log Rank · p = 0.8664 · Hazard ratio (hr): 0.982 · 95% CI 0.80 to 1.21
SecondaryClinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 7

Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

Time frame:
Day 7
Reported as:
Number · Percentage of participants
Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 7
Percentage of participantsRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Category 121.919.4
Category 24.35.6
Category 317.620.1
Category 430.029.4
Category 59.510.0
Category 612.912.1
Category 73.83.3
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Regression, Logistic · p = 0.9569 · Odds ratio (or): 1.01 · 95% CI 0.75 to 1.35
SecondaryClinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 21

Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

Time frame:
Day 21
Reported as:
Number · Percentage of Participants
Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 21
Percentage of ParticipantsRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Category 162.464.3
Category 21.41.2
Category 34.84.7
Category 42.94.4
Category 56.75.6
Category 67.15.8
Category 714.814.0
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Regression, Logistic · p = 0.6331 · Odds ratio (or): 1.09 · 95% CI 0.78 to 1.52
SecondaryClinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 28

Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

Time frame:
Day 28
Reported as:
Number · Percentage of Participants
Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 28
Percentage of ParticipantsRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Category 167.166.4
Category 21.41.4
Category 31.03.5
Category 42.93.0
Category 54.33.7
Category 63.83.7
Category 719.518.2
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Regression, Logistic · p = 0.9622 · Odds ratio (or): 0.99 · 95% CI 0.70 to 1.40
SecondaryClinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 60

Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

Time frame:
Day 60
Reported as:
Number · Percentage of Participants
Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 60
Percentage of ParticipantsRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Category 170.072.2
Category 21.40.7
Category 31.01.4
Category 41.41.6
Category 50.50.7
Category 600.7
Category 725.722.7
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Regression, Logistic · p = 0.4850 · Odds ratio (or): 1.14 · 95% CI 0.79 to 1.64
SecondaryProportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline (Participants Who Did Not Require Mechanical Ventilation at Baseline)

Day 28: Participants who withdraw or die prior to Day 28 are assumed to have required mechanical ventilation. Participants without mechanical ventilation prior to discharge are assumed not to have required mechanical ventilation unless they die by Day 28, which are counted as an event. Day 60: Participants who withdraw or die prior to Day 60 are assumed to have required mechanical ventilation. Participants without mechanical ventilation prior to discharge are assumed not to have required mechanical ventilation unless they die by Day 60, which are counted as an event.

Time frame:
Day 28 and Day 60
Reported as:
Number · Percentage of Participants
Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline (Participants Who Did Not Require Mechanical Ventilation at Baseline)
Percentage of ParticipantsRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Day 2829.8 (23.3 to 36.3)27.5 (23.0 to 32.0)
Day 6031.4 (24.7 to 38.0)28.8 (24.2 to 33.5)
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Cochran-Mantel-Haenszel · p = 0.5915 · Weighted % difference: -2.2 · 95% CI -10.2 to 5.9
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Cochran-Mantel-Haenszel · p = 0.5494 · Weighted % difference: -2.5 · 95% CI -10.5 to 5.6
SecondaryProportion of Participants Who Are Alive and Free of Respiratory Failure at Day 28 and Day 60 (Participants Requiring Mechanical Ventilation at Baseline)
Time frame:
Day 28 and Day 60
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Are Alive and Free of Respiratory Failure at Day 28 and Day 60 (Participants Requiring Mechanical Ventilation at Baseline)
Percentage of ParticipantsRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Day 2854.5 (33.7 to 75.4)40.7 (28.1 to 53.2)
Day 6063.6 (43.5 to 83.7)47.5 (34.7 to 60.2)
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Cochran-Mantel-Haenszel · p = 0.2590 · Weighted % difference: -14.1 · 95% CI -37.4 to 9.2
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Cochran-Mantel-Haenszel · p = 0.2290 · Weighted % difference: -14.6 · 95% CI -37.0 to 7.8
SecondaryDuration of Mechanical Ventilation (Participants Requiring Mechanical Ventilation at Baseline) up to Day 28

Participants who die by Day 28 are assigned a duration of 28 days.

Time frame:
Up to Day 28
Reported as:
Mean · Days
Duration of Mechanical Ventilation (Participants Requiring Mechanical Ventilation at Baseline) up to Day 28
DaysRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Duration of Mechanical Ventilation (Participants Requiring Mechanical Ventilation at Baseline) up to Day 2816.7 (11.9 to 21.5)19.6 (16.8 to 22.4)
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Regression, Linear · p = 0.2434 · Mean difference (final values): 3.1125 · 95% CI -2.16 to 8.38
SecondaryDifference in Mortality at Days 14, 28, and 60
Time frame:
Days 14, 28, and 60
Reported as:
Number · Percentage of Participants
Difference in Mortality at Days 14, 28, and 60
Percentage of ParticipantsRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Day 149.5 (5.6 to 13.5)10.0 (7.2 to 12.8)
Day 2819.5 (14.2 to 24.9)18.1 (14.5 to 21.8)
Day 6025.7 (19.8 to 31.6)22.6 (18.6 to 26.5)
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Cochran-Mantel-Haenszel · p = 0.8222 · Weighted % difference: 0.6 · 95% CI -4.4 to 5.6
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Cochran-Mantel-Haenszel · p = 0.6944 · Weighted % difference: -1.3 · 95% CI -7.8 to 5.2
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Cochran-Mantel-Haenszel · p = 0.3919 · Weighted % difference: -3.0 · 95% CI -10.1 to 4.0
SecondaryTime to Recovery up to Day 28

Defined as the time from randomization to the time when an ordinal scale category of 2 (non-ICU hospital ward or "ready for hospital ward" not requiring supplemental oxygen) or better is observed, not followed by ordinal scale category \>2 or death. Participants who die are censored at day 28. 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

Time frame:
Up to Day 28
Reported as:
Median · Days
Time to Recovery up to Day 28
DaysRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Time to Recovery up to Day 2813.0 (10.0 to 15.0)13.0 (11.0 to 14.0)
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Log Rank · p = 0.6778 · Hazard ratio (hr): 0.957 · 95% CI 0.78 to 1.18
SecondaryProportion of Participants Who Are Discharged or "Ready for Discharge" up to Day 28

Defined as hospital discharge or "Ready for Discharge" not followed by ordinal scale category \>1, hospital readmission or death. 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death

Time frame:
Up to Day 28
Reported as:
Number · Percentage of participants
Proportion of Participants Who Are Discharged or "Ready for Discharge" up to Day 28
Percentage of participantsRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Proportion of Participants Who Are Discharged or "Ready for Discharge" up to Day 2867.1 (60.8 to 73.5)66.0 (61.6 to 70.5)
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Cochran-Mantel-Haenszel · p = 0.7692 · Weighted % difference: -0.9 · 95% CI -8.7 to 6.8
SecondaryProportion of Participants Who Require Initiation of Mechanical Ventilation Post-baseline or Die up to Day 28

Participants already on mechanical ventilation at baseline are only counted as an event if death occurs.

Time frame:
Up to Day 28
Reported as:
Number · Percentage of participants
Proportion of Participants Who Require Initiation of Mechanical Ventilation Post-baseline or Die up to Day 28
Percentage of participantsRemdesivir + Placebo (RDV+PBO) - mITT PopulationRemdesivir + Tocilizumab (RDV+TCZ) - mITT Population
Proportion of Participants Who Require Initiation of Mechanical Ventilation Post-baseline or Die up to Day 2829.0 (22.9 to 35.2)28.6 (24.3 to 32.9)
Statistical analysis
  • Remdesivir + Placebo (RDV+PBO) - mITT Population vs Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population · Cochran-Mantel-Haenszel · p = 0.9334 · Weighted % difference: -0.3 · 95% CI -7.8 to 7.2
Other pre-specifiedPercentage of Participants With Adverse Events (AEs) Tabulated by Severity

AEs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4: Life-threatening consequences; urgent intervention indicated Grade 5: Death related to AE Participants are counted at the highest AE grade experienced.

Time frame:
Up to Day 60
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) Tabulated by Severity
Percentage of participantsRemdesivir + Placebo (RDV+PBO) - Safety PopulationRemdesivir + Tocilizumab (RDV+TCZ) - Safety Population
Grade 19.910.5
Grade 221.128.2
Grade 310.311.2
Grade 44.24.9
Grade 525.822.6
Other pre-specifiedProportion of Participants With Any Post-Treatment Infection
Time frame:
Up to Day 60
Reported as:
Number · Percentage of Participants
Proportion of Participants With Any Post-Treatment Infection
Percentage of ParticipantsRemdesivir + Placebo (RDV+PBO) - Safety PopulationRemdesivir + Tocilizumab (RDV+TCZ) - Safety Population
Serious infections27.722.6
Infections35.733.3
Opportunistic infections2.31.4

Adverse events

Collected over Up to Day 60. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Remdesivir + Placebo (RDV+PBO)55/213 (25.8%)76/213 (35.7%)70/213 (32.9%)
Remdesivir + Tocilizumab (RDV+TCZ)97/429 (22.6%)141/429 (32.9%)144/429 (33.6%)
Most frequent serious events
Showing 10 of 125
Most frequent serious events
EventRemdesivir + Placebo (RDV+PBO)Remdesivir + Tocilizumab (RDV+TCZ)
COVID-19 pneumoniaInfections and infestations27/21336/429
Acute kidney injuryRenal and urinary disorders14/21321/429
Septic shockInfections and infestations10/21323/429
PneumoniaInfections and infestations6/21321/429
COVID-19Infections and infestations8/21314/429
SepsisInfections and infestations6/21311/429
Renal impairmentRenal and urinary disorders5/2131/429
Pneumonia bacterialInfections and infestations4/2135/429
HypotensionVascular disorders4/2134/429
PneumothoraxRespiratory, thoracic and mediastinal disorders1/2137/429
Most frequent other events
Most frequent other events
EventRemdesivir + Placebo (RDV+PBO)Remdesivir + Tocilizumab (RDV+TCZ)
ConstipationGastrointestinal disorders25/21354/429
AnaemiaBlood and lymphatic system disorders14/21313/429
Transaminases increasedInvestigations10/21325/429
HypotensionVascular disorders12/21319/429
Acute kidney injuryRenal and urinary disorders11/21324/429
HypokalaemiaMetabolism and nutrition disorders6/21323/429
Urinary tract infectionInfections and infestations11/21320/429
HyperglycaemiaMetabolism and nutrition disorders9/21322/429

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Remdesivir + Placebo (RDV+PBO)Remdesivir + Tocilizumab (RDV+TCZ)Total
Mean58.2 ± 13.660.1 ± 13.359.5 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)Remdesivir + Placebo (RDV+PBO)Remdesivir + Tocilizumab (RDV+TCZ)Total
Female73167240
Male142267409
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Remdesivir + Placebo (RDV+PBO)Remdesivir + Tocilizumab (RDV+TCZ)Total
Hispanic or Latino125209334
Not Hispanic or Latino88208296
Unknown or Not Reported21719
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Remdesivir + Placebo (RDV+PBO)Remdesivir + Tocilizumab (RDV+TCZ)Total
American Indian or Alaska Native448
Asian51722
Native Hawaiian or Other Pacific Islander3710
Black or African American205272
White154282436
More than one race2911
Unknown or Not Reported276390
08

Study locations

54 sites
  • Valleywise Health Medical Center
    Phoenix, Arizona 85008, United States
  • eStudySite - Chula Vista - PPDS
    Chula Vista, California 91911, United States
  • Hoag Hospital Irvine
    Irvine, California 92612, United States
  • Providence St Johns Health Center
    Santa Monica, California 90404, United States
  • Yale University School of Medicine; HIV Clinical Trials Program
    New Haven, Connecticut 06501, United States
  • Medstar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Holy Cross Hospital Inc
    Fort Lauderdale, Florida 33308, United States
  • Larkin Community Hospital Palm Springs Campus (Hialeah)
    Hialeah, Florida 33012, United States
  • University of Miami Miller School of Medicine; Clinical Reseach Building
    Miami, Florida 33136, United States
  • Larkin Community Hospital
    South Miami, Florida 33143, United States
  • St Luke's Health System; Rheumatology Research
    Boise, Idaho 83702, United States
  • Advocate Christ Medical Center
    Oak Lawn, Illinois 60453, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Boston Medical Center
    Boston, Massachusetts 02118-2393, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
  • Henry Ford Medical Center
    Novi, Michigan 48322, United States
  • St. Michael'S Medical Center
    Newark, New Jersey 07102, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • Wyckoff Heights Medical Center
    Staten Island, New York 11237, United States
  • Novant Health Clinical Research
    Charlotte, North Carolina 28204, United States
  • OhioHealth Research Institute
    Columbus, Ohio 43214, United States
  • Providence Saint Vincent's Medical Center
    Portland, Oregon 97225, United States
  • Lehigh Valley Hospital
    Allentown, Pennsylvania 18103, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • The Liver Institute at Methodist Dallas
    Arlington, Texas 76012, United States
  • Baylor Scott and White Medical Center - College Station
    College Station, Texas 77845, United States
  • Baylor University Medical Center
    Dallas, Texas 75231, United States
  • Baylor St. Luke's Medical Center
    Houston, Texas 77030, United States
  • Ben Taub General Hospital - HCHD
    Houston, Texas 77030, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Baylor Scott & White Medical Center - Irving
    Irving, Texas 75061, United States
  • Baylor Scott & White Hospital - Plano
    Plano, Texas 75093, United States
  • Baylor Scott & White Health
    Temple, Texas 76502, United States
  • Intermountain LDS Hospital
    Salt Lake City, Utah 84143, United States
  • The Providence Regional Medical Center Everett
    Everett, Washington 98201, United States
  • West Virginia University Hospital
    Morgantown, West Virginia 26506, United States
  • Santa Casa de Misericordia de Belo Horizonte
    Belo Horizonte, MG 30150-221, Brazil
  • Hospital Nossa Senhora das Graças; Setor de Pesquisa em Neurologia
    Curitiba, PR 80810-040, Brazil
  • Instituto de Pesquisa Clinica Evandro Chagas - IPEC FIOCRUZ
    Rio de Janeiro, RJ 21045-900, Brazil
  • CEMEC - Centro Multidisciplinar de Estudos Clínicos
    Sao Bernardo Do Campo, SP 09715-090, Brazil
  • Hospital de Base de Sao Jose do Rio Preto
    Sao Jose do Rio Preto, SP 15090-000, Brazil
  • Instituto de Infectologia Emilio Ribas
    Sao Paulo, SP 01246-000, Brazil
  • Instituto do Coração - HCFMUSP
    Sao Paulo, SP 05403-900, Brazil
  • Medsi Clinic
    Moscow, Adygeja 143442, Russian Federation
  • O.M. Filatov City Clinical Hospital #15; Department of Surgery
    Moskva, Moskovskaja Oblast 111539, Russian Federation
  • City Pokrovskaya Hospital
    Sankt-peterburg, Sankt Petersburg 199106, Russian Federation
  • City Clinical Hospital # 52
    Moscow, 123182, Russian Federation
  • Hospital Universitario de Bellvitge
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Universitario Principe de Asturias; Medicina Interna - Servicio de Enfermedades Infecciosas
    Alcala de Henares, Madrid 28005, Spain
  • Hospital Universitario HM Torrelodones
    Torrelodones, Madrid 28250, Spain
  • Hospital General Universitario de Guadalajara
    Guadalajara, 19002, Spain
  • Hospital Universitario Fundacion Jimenez Diaz.
    Madrid, 28040, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Feb 2021, 7 months.

Results were first posted in Feb 2022, 1 year after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 7 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2020
First posted
Jun 1, 2020
StartActual
Jun 16, 2020
Primary completionActual
Feb 1, 2021
CompletionActual
Mar 8, 2021
Results first posted
Feb 14, 2022
Last update
Feb 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04409262
Lead sponsor
Hoffmann-La Roche
Collaborators
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 1, 2020
Start date
Jun 16, 2020
Primary completion
Feb 1, 2021
Completion
Mar 8, 2021
Results posted
Feb 14, 2022
Last update
Feb 14, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion